A revenue ranking of 8 listed companies providing contract clinical laboratory testing services, along with a comparison of key indicators, has been published. Indicators such as market capitalisation and PER are shown for each stock, with some fields displayed as “-” for stocks with insufficient data.
The contract clinical laboratory testing market comprises 8 listed companies, which can be compared using indicators including revenue, operating profit, market capitalisation, PER, PBR, ROE, ROA, ROIC and EV/EBITDA.
PER is the price/earnings ratio, and PBR is the price/book-value ratio. ROE, ROA and ROIC are used to assess profitability, while EV/EBITDA is used to assess enterprise value. Some fields may be displayed as “-” for stocks for which data cannot be obtained.
The table lists the rank, code, stock name and each indicator. It shows that M3 (Code 2413) ranks first, with market capitalisation of approximately ¥1,252,651 million, revenue of approximately ¥351,363 million, operating profit of approximately ¥73,547 million, EV/EBITDA of 12.4, ROE of 12.5%, ROA of 7.7% and net cash of approximately ¥124,618 million.
The article also provides information about ancillary services, including stock charts and earnings schedules, as well as guidance on free membership registration.